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Abstract
Background: Depression is a widespread and serious disease often accompanied by a high degree of suffering and
burden of disease. The lack of integration between different care providers impedes guideline-based treatment. This
constitutes substantial challenges for the health care system and also causes considerable direct and indirect costs.
To face these challenges, the aim of this project is the implementation and evaluation of a guideline-based stepped
care model for depressed patients with six treatment options of varying intensity and setting, including
low-intensity treatments using innovative technologies.
Methods/design: The study is a randomized controlled intervention trial of a consecutive sample of depressive
patients from primary care assessed with a prospective survey at four time-standardized measurement points within
one year. A cluster randomization at the level of participating primary care units divides the general practitioners
into two groups. In the intervention group patients (n = 660) are treated within the stepped care approach in a
multiprofessional network consisting of general practitioners, psychotherapists, psychiatrists and inpatient care
facilities, whereas patients in the control condition (n = 200) receive routine care. The main research question
concerns the effectiveness of the stepped-care model from baseline to t3 (12 months). Primary outcome is the
change in depressive symptoms measured by the PHQ-9; secondary outcomes include response, remission and
relapse, functional quality of life (SF-12 and EQ-5D-3 L), other clinical and psychosocial variables, direct and indirect
costs, and the incremental cost-effectiveness ratio. Furthermore feasibility and acceptance of the overall model as
well as of the separate treatment components are assessed.
Discussion: This stepped care model integrates all primary and secondary health care providers involved in the
treatment of depression; it elaborates innovative and evidence-based treatment elements, follows a stratified
approach and is implemented in routine care as opposed to standardized conditions. In case of positive results, its
sustainable implementation as a collaborative care model may significantly improve the health care situation of
depressive patients as well as the interaction and care delivery of different care providers on various levels.
Trial registration: This study is registered with ClinicalTrials.gov, number NCT01731717 (date of registration: 24
June 2013).
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Background
Depression is one of the most widespread mental disor-
ders [1] and involves a high degree of personal suffering,
a high burden of disease and serious impairments [2].
Thus it constitutes a substantial challenge for the health
care system and causes considerable direct and indirect
costs [3]. Detailed estimations predict a further increase
in depression-related disease burden in the next 20 years;
depression will represent the second most important
factor for impairment and premature mortality after
cardiovascular diseases in highly economically developed
countries [2].
Health care is confronted with several central areas of
concern in the diagnosis and treatment of depression:
1. Depression often remains undetected or is diagnosed
late: Especially in the primary care setting, the
current detection rate of 50% to 68% needs to be
optimized [4-8].
2. Patients with depression often do not receive
evidence-based treatments or the treatment is
initiated only after a long delay [8,9]. Adults in urban
areas have to wait 12.5 weeks on average for a first
diagnostic contact, while in rural areas the waiting
time for psychological treatments comprises up to
17 weeks, according to a national survey conducted
by the German federal psychotherapist association
[10]. Depressive patients on waiting lists suffer from
a high burden of disease for many months [11].
3. The initiation of treatment for patients with
depression is often carried out with a rather
unsystematic selection related to the type, the
intensity of treatment and the adequate allocation of
resources. This may increase the risk of undersupply
on the one hand and oversupply on the other hand
[12]. In this respect, especially low-intensity
treatment options (e.g. structured self-help
approaches) systematically integrated into the health
care system are missing.
4. When treatments are initiated, an integrated care
spanning different sections of the health care system
is complicated due to the fragmentation of health
services and the absence of an appropriate interface
management (e.g. between primary and secondary
care and between out- and inpatient care) [13].
In order to overcome these deficits it is necessary to
develop, implement and evaluate guideline-oriented and
evidence-based models of care that include 1) better de-
tection rates of depression, 2) the prompt offer and access
to evidence-based treatments, 3) a systematic treatment
selection with the option of choosing between different
levels of treatment intensity to initiate a tailored and
efficient treatment and 4) multi-professional cooperation
of the providers across different health care sectors in
order to ensure an integrated pathway through the health
care system.
Stepped care is a promising approach for improved de-
pression care [12,14,15], a concept recommended in na-
tional and international guidelines [16-18]. Stepped care
is based on treating patients with the most adequate treat-
ment of lowest intensity while continuously monitoring
their treatment progress. If clinically necessary, patients
are stepped up to a more intensive intervention form. The
treatment level is adjusted gradually whenever indicated
until a satisfactory health status is achieved [12]. Katon
and colleagues [19-21] first demonstrated in the 1990s the
effectiveness of several comprehensive models to improve
the treatment of patients with depression in primary care:
They found that a stepped care model consisting of
psychoeducation and a higher frequency of psychiatric
consultations led to increased medication compliance and
reduced depressive symptoms in comparison to routine
care, suggesting its effectiveness and cost-effectiveness
[15,21]. Van’t Veer-Tazelaar et al. showed how a stepped
care model (watchful waiting, bibliotherapy, short term
psychotherapy and medication) for elderly patients with
subclinical depression reduced the risk for the occurrence
of a clinical depression by approximately 50% [22].
Taking these promising results into account, we devel-
oped and implemented an extended stepped care model
into routine care integrating the following aspects:
1. Implementation of a guideline-oriented and
evidence-based stepped care model within a
multi-professional network across different health
care sectors consisting of general practitioners,
psychiatrists and psychotherapists in out- and
inpatient care.
2. Systematic screening and structured diagnostic
procedures in primary care as the basis for an
appropriate delivery of different interventions
following a stepped care approach.
3. Patients are treated within this network with the
goal of delivering a prompt and appropriate
evidence-based treatment with an improved
information exchange between the involved
providers.
4. Patients receive the treatment step which they are
most likely to benefit from (as opposed to every
patient receiving the least intense step first and
being stepped up only if this step is not effective
enough).
5. Introduction of evidence-based treatment options
with different levels of intensity which are not yet
available in German routine care. We include
modern e-health interventions like Internet- and
telephone-based psychotherapy as well as the more
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traditional approach of bibliotherapy in the stepped
care model [17,23].
The aim of the randomized controlled trial is to evaluate
this guideline-oriented and evidence-based stepped care
model for depressive patients comprising six treatment
options of varying intensity and setting, including innova-
tive technologies. The evaluation refers to the effectiveness
and the cost-effectiveness of this complex intervention
under the conditions of routine care.
Methods/design
Setting
The study is embedded in the intersectoral research
network psychenet: Hamburg Network for Mental Health
(2011–2014), a research and development project funded
by the German Federal Ministry for Education and Re-
search (BMBF) [24]. It aims at the improvement of the
city’s population’s mental health by implementing new
integrated health care networks based on evidence for
effective treatment methods and by evaluating selected
innovations and complex interventions in the region of
Hamburg. The overall project is organized in 11 sub-
projects. While the first five sub-projects (1–5) facilitate
mental health across different areas of disease by improv-
ing information and education, fostering occupational
health or strengthening the participation of sufferers and
their family members, five illness-specific health networks
have been conceived (sub-projects 6–10). A general ac-
companying sub-project (11) ensures the quality of the
interventions in all sub-projects and conducts evaluative
and health-economic investigations [24]. This article de-
scribes the study protocol of the health network depres-
sion (sub-project 7).
Objectives
Primary objective of this randomized controlled trial is
to examine the effectiveness of a complex intervention
(stepped care model, SCM) assessed through the reduc-
tion in depression severity within a network of general
practitioners (GP), psychiatrists and psychotherapists in
routine care.
Secondary objectives are to examine the effectiveness
of SCM in terms of response, remission and health-related
quality of life as well as to examine its cost-effectiveness.
Further objectives are the evaluation of the process quality
and of patients’ and practitioners’ satisfaction with SCM.
Study design
The study is designed as a randomized controlled inter-
vention trial of a consecutive sample of depressive patients
from primary care assessed with a prospective multiple
time point survey. GPs are divided into two groups by
undertaking a cluster randomization on the level of the
participating primary care units. Patients recruited by GPs
in the intervention group (IG) are treated within the
stepped care approach (SCM, see section Intervention).
Patients recruited by GPs in the control group (CG)
receive treatment as usual (TAU). Both patient groups
are compared with respect to their treatment response
within a one-year period. The scientific approach is pri-
marily quantitative with additional qualitative analyses
regarding feasibility and acceptance of the SCM by
patients as well as by out- and inpatient care providers.
Primary hypothesis
The trial evaluates the primary hypothesis that the SCM
condition (IG) outperforms the TAU condition (CG) re-
garding the primary outcome parameter (PHQ-9), i.e. that
stepped care is more effective than treatment as usual in
depressive symptom reduction after 12 months.
Randomization
Cluster-randomization is performed in order to allocate
confounding variables in equal parts to both study condi-
tions and thus to control for potential bias in order to guar-
antee internal validity. In this study, cluster-randomization
is undertaken at the level of the participating GP practices,
which are allocated to either IG or CG in a 3:1 ratio. The
process of randomization is conducted by a computer pro-
gram by minimization based on the GP’s practice size (sin-
gle practice vs. group practice), the location of the practice
within Hamburg classified into the two categories (central
vs. peripheral) and income level of the practice’s local dis-
trict classified into three categories (low, middle and high).
Criteria for selection of clustering variables are relevance
and availability. We assume that each GP in the 49 partici-
pating practices is able to recruit 15–25 patients. A total of
36 practices is randomized into the IG and 13 practices into
the CG.
Ethical approval
The study protocol was approved by the responsible local
Ethics Committee in Hamburg and will be conducted
according to the principles of the Declaration of Helsinki
(2013 version).
Study population and recruitment
Patients
The recruitment of the patients in the IG and CG is
carried out by the participating GPs and comprises three
guideline-recommended steps of screening and assess-
ment as displayed in Figure 1: First, by applying a 2-item-
checklist (risk-checklist) the GP systematically identifies
those patients with diffuse somatic symptoms and/or with
chronic somatic conditions [16,25], i.e. patients at high
risk for depression. For this group of patients, the GP
continues the screening procedure by using a further
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guideline-based 2-item-checklist (main-symptom-check-
list) assessing the main symptoms of depression. A posi-
tive answer in at least one of these questions leads to
the third screening step, an assessment with the depres-
sion module of the Patient Health Questionnaire (PHQ-
9): Patients with a score of five or more points meet the
study’s basic inclusion criterion and are informed about
the study. After giving informed consent, patients
receive their baseline questionnaire.
Inclusion and exclusion criteria
Inclusion criteria are a minimum age of 18, five or more
points on PHQ-9 and informed consent. Patients with
insufficient knowledge of the German language or a health
situation that does not allow questionnaire completion are
excluded. Neither somatic nor mental comorbidities are
exclusion criteria. However, if a mental disorder other
than depression is the main treatment focus patients are
also excluded from the study.
Sample size and power calculation
We aim to gain a sample size that permits a small to
moderate effect size between SCM and TAU to be de-
tected with a statistical power of 80%. A small to moderate
effect size is defined as eta2 = 0.0344 (or f = 0.175 accord-
ing to Cohen [26]). We expect a reduction of the error
variance of approximately 20% by including initial symp-
tom severity (PHQ-9 at t0) as a covariate (which can be
expected to be uncorrelated to the study conditions due
to randomization). This leads to an adjusted effect size of
eta2 = 0.042 (f = 0.209). In this respect and based on α =
0.05 a sample of n = 92 patients in each study condition is
required for our main analysis. As we presume a drop-out
rate of 20% in the IG an initial sample of n = 110 patients
is needed in this group to answer the main research ques-
tion. In order to run further separate analyses for each of
the six treatment options within the SCM (and assuming
an equal distribution of patients onto each option) we in-
clude 6*110 patients in the intervention group. As for the
control group, a larger rate of drop-out has to be expected
(approximately 50%, due to less personal involvement), a
total of N = 200 patients is to be recruited in this study
condition. Therefore, a total of N = 860 depressive patients
are to be included in the study.
For the primary endpoint changes in PHQ-9 to baseline
after 12 months we assume a small to moderate effect size
defined as Cohen's d = 0.4 and set the significance level
to 0.05 (two-sided). With these settings a sample size of
100 patients in each group is required to achieve a
power of 80%. 2 × 100 patients need to be included if
the randomization occurs at the patient level. With an
assumed intra-cluster correlation (ICC) of 0.05 and 20
included patients per cluster on average a design effect
of 1.95 is calculated, increasing the sample size to 200
patients and 10 practices per group.
We decide to recruit the threefold number of patients
in the intervention group because we would like to ob-
tain detailed knowledge about the six treatment options.
Figure 1 Design of the study comparing a stepped care model (SCM) to treatment as usual (TAU) for patients with depression.
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And so we assume to have a sufficient number of
patients in each of the treatment options. This approach
results in 860 patients and 40 practices to recruit with a
3:1 allocation to the intervention and the control group,
respectively.
Intervention
Treatment condition
The SCM is embedded in a multiprofessional network
(see below) and consists of the following components:
Diagnostic process and treatment selection
GPs of the intervention group continue the diagnostic
process with a paper-pencil ICD-10-checklist to deter-
mine depression type and severity. Patients are given
psycho-education about depression including evidence-
based patient information. The decision about which
evidence-based treatment option to carry out is made in
cooperation with the patient (shared decision-making).
Treatment interventions are allocated with consider-
ation to depression severity and patient preference fol-
lowing guideline recommendations. The six treatment
options (as well as the step 1 option of watchful waiting),
the rationale for treatment selection within stratified
stepped care and the care provider responsible for each
treatment option are displayed in Table 1. While these
recommendations offer a rationale orientation for treat-
ment decisions, the assessment of the individual’s prefer-
ences may lead to different individual treatment decisions.
Step 2.a/2.b/2 plus
Three forms of low-intensity treatment for patients with
mild depressive disorders are offered: 1) step 2.a: biblio-
therapy; 2) step 2.b: the Internet-based self-management
program “deprexis®” and 3) step 2 plus: telephone-based
psychotherapy with a previous face-to-face contact
conducted by a licensed psychotherapist.
In bibliotherapy, patients work independently and at
their own pace with a cognitive-behavioral self-help book
(“Selbsthilfe bei Depressionen”) [27], comprising detailed
psycho-education and exercises with a focus on behavioral
activation and cognitive restructuring. Personal guidance
is limited in its scope and is carried out by the GP who
gives an initial introduction to the intervention, hands
out the book and monitors the progress of patients in
this step.
In Internet-based self-management, the GP informs the
patient about the program and the procedures and provides
the patient with a personal license to register to the soft-
ware. The program deprexis® is a certified medical product
based on a cognitive-behavioral approach that allows
patients to work independently and at their own pace [28].
The program consists of 12 interactive simulated conversa-
tions including detailed psycho-education and exercises. It
focuses on behavioral activation and cognitive restructur-
ing. For each patient, the program is tailored individually in
terms of level of detail, language and personal relevance.
The GP monitors and accompanies the patient during the
three months scheduled to complete the program.
The telephone-based psychotherapy is the translated
and adapted version of a specific intervention program
[29-31] developed by researchers in Seattle. It includes a
patient workbook as well as a therapist manual and will
be evaluated in two conditions (delivery with vs. without
additional motivating letters from the psychotherapist
after each session). It comprises 8 to 12 telephone
contacts (20 to 40 minutes) which are carried out weekly
and - at a later treatment stage - biweekly. This 3-month
structured program also follows a cognitive behavioral
approach with the main focus on behavioral activation
and cognitive restructuring. As the level of guidance and
intensity in telephone-based psychotherapy is higher than
in bibliotherapy and Internet-based self-management, it
can also be carried out with patients suffering from mod-
erate depression, especially if they decline step 3 (psycho-
therapeutic or pharmacological treatment).
Step 3 and Step 4
Psychotherapy and/or pharmacotherapy (as stand-alone
and as combination treatment) are conducted by health
care providers in outpatient care (psychotherapy: psy-
chologists or physicians licensed as psychotherapists;
Table 1 Criteria for systematic treatment indication and description of responsible care providers for each step
Severity of the depressive disorder Step in the
SCM
Intervention Responsible care provider
Mild depressive disorder, duration: up
to two weeks
1 Watchful waiting (active monitoring) for 2 weeks GP
Mild depressive disorder, duration: over
two weeks
2.a or 2.b Bibliotherapy or Internet-based self-help program GP
Mild to moderate depressive disorder,
duration: over two weeks
2 plus Telephone-based psychotherapy Psychotherapist
Moderate depressive disorder 3.a or 3.b Psychotherapy or pharmacotherapy Psychotherapist or psychiatrist/GP
Severe depressive disorder without/
with suicidality
4 Combination therapy: psycho- and
pharmacotherapy (inpatient or outpatient setting)
Psychotherapist and psychiatrist; clinic
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pharmacotherapy: psychiatrists or GPs) from routine
care who undergo initial training and take part in four
quality circles per year (see next section).
Monitoring
Depression severity is systematically monitored by the
responsible care provider within defined time intervals
in order to ensure that a potential under- or oversupply
is detected as quickly as possible. During monitoring
patients fill out the PHQ-9 which is checked by the pro-
vider. Additionally, the care provider (GP, psychiatrist
or psychotherapist) completes a monitoring sheet. This
checklist assesses treatment-related information and is
designed to facilitate decisions regarding further treat-
ment (continuing current treatment, stepping up or
down, treatment termination).
Multiprofessional network
A necessary framework for the SCM is its integration in
a network consisting of the relevant care providers
involved in the treatment of depressive patients, i.e. GPs,
psychotherapist, psychiatrists and inpatient care facilities.
To build such a network these professional groups were
sent information and personal invitations to join the
project. Additionally, articles in professional journals ad-
vertising the study were published and professionals were
contacted via telephone.
The main focus of the network is facilitation and en-
hancement of information exchange and communication
between all network care providers of the network in
order to increase the quality of patients’ health care. An-
other important aspect is the prompt referral to a sec-
ondary care provider like psychotherapist or psychiatrist.
Information exchange about available treatment capaci-
ties in secondary care is enhanced using an online tool
specifically developed for this project. Psychotherapists
and psychiatrists indicate whether they currently have an
available treatment capacity which implies that the psych-
iatrist or psychotherapist is able to offer the patient a first
contact within the next three weeks. This way, GPs are
able to make a reservation for their patients online and
refer them into secondary treatment without delay.
Training and quality standards
Previous to the implementation of the SCM, participat-
ing care providers obtain training regarding the recom-
mendations of the German National Clinical Practice
Guideline for unipolar depression [18], the rationale and
the treatment concept of the SCM and the specific interven-
tions. Each GP is additionally visited by the study team at
least once in his or her practice to review the diagnostic
routines in the everyday routine care. The psychotherapist
for the telephone-based treatment receives special training
and weekly supervision. Within the network, guideline-
based quality standards are defined (e.g. type and fre-
quency of monitoring). To ensure that these standards are
met and to promote the cooperation and information ex-
change between the participating care providers, quarter-
yearly quality circles take place. For the conception of the
initial training and quality circles we could integrate
experiences from former projects [32-35].
Intervention for the control group
Patients in the control condition receive treatment as
usual by their GP and within the regular German health
care system. However, systematic screening with the risk-
checklist, main-symptom-checklist and PHQ-9 are carried
out in both intervention and control group to ensure a
comparable recruitment and inclusion process.
Outcome assessment
The main data collection comprises paper-pencil ques-
tionnaires which are filled out by the patients at four
time points: The baseline questionnaire (t0) is handed out
by the GP at intake and filled out before any treatment be-
gins. The questionnaires 3 months (t1), 6 months (t2) and
12 months (t3) after baseline are sent to the patient’s by
mail. For each completed questionnaire, patients receive
an incentive of 5 €. Patients who fail to send back their
questionnaires are reminded to do so twice by mail.
The primary outcome parameter for effectiveness is the
change in depressive symptoms from baseline to t3
assessed by the PHQ-9. Secondary outcome parameters
are response (defined as a 50% reduction in the PHQ-9
from t0 to t3) and remission (defined as < 5 points in the
PHQ-9 at t3), change in health related quality of life (SF-
12 and EQ-5D-3 L) and further clinical and psycho-social
variables. To evaluate the cost-effectiveness of the SCM,
direct and indirect costs as well as quality-adjusted life
years (QALYs) based on the EQ-5D index are measured
and the incremental cost-effectiveness ratio (ICER) is
computed as further secondary outcomes.
Process analyses refer to treatment paths, decision pro-
cesses and interface management. Additionally, feasibility
and acceptance of the overall model of stepped care and
of its components are analyzed taking patient and care
provider perspectives into account. Table 2 summarizes
the instruments for the patient self-ratings.
Outcome instruments (patient ratings)
Patient Health Questionnaire (PHQ)
The German version [36,37] of the Patient Health Ques-
tionnaire [38] is used. Specific subscales assessing follow-
ing syndromes were selected: major depressive syndrome
(9 items), generalized anxiety syndrome (7 items), somato-
form syndrome (13 items) and panic syndrome (11 items).
Additionally, psychosocial functioning resp. psychosocial
stressors are measured.
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Short Form Health Survey (SF-12)
The SF-12 assesses overall health-related quality of life
and is based on the Short Form 36 Health Survey
[39]. It is composed of the two subscales physical
health and mental health. Scores are computed by
calculating the sum of the 12 weighted items and then
transforming it to a scale from 0 to 100, on which
high scores indicate a high level of health-related
quality of life.
EQ-5D-3 L
This generic self-rating instrument measures health-
related quality of life on five dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/depres-
sion [40,41]. Each dimension has three response categories
that represent three levels of severity (“no problems”/
“some or moderate problems”/“extreme problems”). Add-
itionally, a visual analogue scale allows the general assess-
ment of health-related quality of life. From the EQ-5D-3 L
a preference-based index of health-related quality of life
(EQ-5D index) can be derived [42].
General self-esteem scale (revised version of the
Rosenberg Self-Esteem-Scale)
The scale was originally designed by Rosenberg in 1965
to assess global self-esteem and translated to German
[43]. It contains 5 positively and 5 negatively formulated
items with statements referring to the subject’s global
attitude towards him- or herself. The answers are given
on a four-point scale. After recoding negative items a
total score can be computed.
General self-efficacy scale (GSE)
This self-rating instrument measures global optimistic be-
liefs about one’s self on a one-dimensional scale [44]. The
underlying concept of self-efficacy includes the self-related
expectation to be able to successfully cope with difficult
situations. On ten items formulated as statements, subjects
indicate their level of agreement on a four-point scale.
Self-efficacy for managing and preventing depression
The depression-related self-efficacy is assessed on a ten-
point scale, where subjects indicate the extent of trust in
Table 2 Instruments and measurement points (patient self-ratings)
Measurements
Outcome variables T0 T1 T2 T3
Patient Health Questionnaire (PHQ-D) X X X X
Short Form Health Survey (SF-12) X X X X
EuroQol (EQ-5D-3 L) X X X X
General self-esteem scale (Rosenberg Self-Esteem-Scale RSES) X X X X
General self-efficacy scale (GSE) X X X X
Self-efficacy for management and relapse prevention in depression X X X X
Depression self-management behavior X X X X
Medical treatments and services received during the last 6 months X - X X
Medication during the last 6 months X - X X
Health care utilization during the last 3 resp. 6 months - X X X
Satisfaction with specific treatments during the last 3 resp. 6 months - X X X
Client Satisfaction Questionnaire (CSQ-8) - - - X
Helping Alliance Questionnaire (HAQ) - X X X
Further (controlling) variables T0 T1 T2 T3
Sociodemographics X - - -
Social Support (F-Sozu-14) X - - -
Shared decision-making (SDM-Q-9) X - - -
Treatment motivation (FPTM-23, subscales “psychological burden” and “expectations”) X - - -
Former depression-specific treatments X - - -
Symptom course of depression X - - -
Referral procedures and interface management - X X X
Self-help experiences and habits X - - -
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their own ability to cope with their depressive symptoms
and complaints [45]. Psychometric analyses have con-
firmed the scale’s internal consistency.
Depression-related self-management behavior
These five items cover depression-related self-management
behavior to assess patients’ behavioral strategies for hand-
ling depression [46]. Patients are questioned about the
frequency with which they integrate pleasant and social
activities into everyday life as well as about their attention
regarding depressive symptoms, early warning signs and
situations which put them at risk of depressive episodes.
Health care utilization during the last 3 resp. 6 months,
satisfaction with specific treatments during the last 3
resp. 6 months
These two parts of the questionnaire aim to explore which
offers patients made use of during the last 3 respectively
6 months and how they are perceived and evaluated.
Client Satisfaction Questionnaire (CSQ-8) (German version
ZUF-8)
On eight items, this questionnaire measures the extent
of the patient’s satisfaction with received medical and psy-
chotherapeutic treatment [47,48]. Important aspects are
the interaction between care provider and patient, infor-
mation about received treatment elements and the com-
munication between the care providers.
Helping Alliance Questionnaire (HAQ)
The German short version of this questionnaire consists
of 11 items rated on a six-point scale [49]. The HAQ
assesses the two factors “perceived helpfulness” and “col-
laboration or bonding”. It aims to capture the patient’s
view of the relationship with the psychotherapist and of
process variables. High scores indicate a high level of
relationship quality.
Additional control variables (patient-ratings)
Socio-demographic data
Following socio-demographic data is collected within a
structured questionnaire: age, gender, nationality, family
status, partnership, children, educational background,
vocational training, housing and professional situation.
Social Support (F-Sozu-14)
The 14-item Social Support questionnaire assesses per-
ceived social support (practical and emotional support).
By computing means, a total score from 1 to 5 points
can be calculated [50].
Shared decision-making (SDM-Q-9)
This instrument measures the extent to which the pa-
tient is involved in the decision-making process for the
treatment [51]. It consists of nine items rated on a
6-point scale.
Treatment motivation: specific subscales of the German
Psychotherapy Motivation Questionnaire (Fragebogen für
Psychotherapiemotivation FPTM-23)
To explore the different aspects of patients’ self-rated mo-
tivation for psychotherapeutic treatment the short version
of this instrument with 23 items rated on a 4-point scale
is employed [52].
Further self-developed variables
Depression-specific treatments received prior to the study,
medical treatments and services received during the last
6 months and medication during the last 6 months,
symptom course of depression, referral procedures and
interface management, self-help experience and habits.
Additional instruments (health care provider ratings)
Documentation forms for screening, diagnostic and
monitoring
These forms help to facilitate and support the diagnostic
and treatment process (and are therefore elements of
the intervention itself ), as well as to document clinical
processes for research purpose: They are used to analyze
clinical treatment pathways and their quality as well as
to draw conclusions about care providers’ adherence to
the guidelines.
Ratings on feasibility and acceptance
Each health care provider in the SCM fills out a ques-
tionnaire assessing the feasibility of and satisfaction and
experiences with the SCM as a whole, the single compo-
nents of the SCM (especially the innovative elements)
and the quality of the multi-professional network.
Structural information
Information regarding structural and organizational as-
pects of the primary care practices and the GPs are gath-
ered in an interview at the beginning of the study. Issues
covered are the size of the practices as well as their
equipment, catchment area, workload and proportions
of different work aspects (patient contacts, administra-
tive tasks, etc.).
Statistical analyses
The primary analysis of the change in depressive symp-
toms from baseline to t3 assessed by the PHQ-9 will be
based on the ITT-population. In case of missing follow-
up values, a last-observation carried forward (LOCF)
imputation will be performed, that is, the baseline deter-
mination will be imputed as follow-up determination. A
linear mixed model will be calculated with group (SCM/
TAU) as a fixed effect and practice as a random effect
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under control of the baseline value of the PHQ-9 as
covariate.
Only the result of this primary efficacy analysis will be
interpreted in a confirmatory manner.
The secondary endpoints will be examined in an ex-
ploratory manner with appropriate procedures, including
subgroup analysis of sex, socio-economic status and symp-
tom severity of patients. Analyses of secondary endpoints
should provide an indication on the consistency of the re-
sults from the evaluation of primary endpoints. The effects
of the selected strata in the minimization algorithm on the
primary and secondary endpoints will be evaluated add-
itionally. Regression coefficients, 95% confidence intervals
and p values will be reported. The analyses will be con-
ducted with the newest SPSS version.
With regard to the assessment of cost-effectiveness
direct and indirect costs will be calculated. Administrative
and market prices will be used to value resource utilization.
The human capital approach will be employed to value
productivity losses. As effect measure QALYs will be calcu-
lated from the EQ-5D-3 L. The cost-effectiveness analysis
will be performed from a societal perspective. As point
estimate of cost-effectiveness the ICER (incremental
costs per QALY) will be calculated. To assess the uncer-
tainty of the results a cost-effectiveness-acceptability-
curve (CEAC) based on non-parametric bootstrapping
will be computed. A net-monetary benefit regression
analysis will be performed.
Discussion
This randomized-controlled intervention study investigates
the effectiveness and efficacy of a stepped-care model for
patients suffering from depression. The model’s aim is to
offer adequate and integrated care by providing six differ-
ent intervention options of varying intensity levels and by
implementing the recommendations of the German Na-
tional Clinical Practice Guideline for unipolar depression.
A strength of the study is that the stepped-care model
under investigation integrates the professional providers
of primary and secondary care involved in the treatment
of depression (GPs, psychiatrists and psychotherapists in
out- and inpatient units) within one network in order
to optimize treatment paths. Evaluating new innova-
tive treatment elements and implementing the SCM
in routine care - as opposed to standardized “ideal”
conditions - are two further important characteristics
of this study. The evaluation of the former aspect in-
vestigates whether these innovative treatments could
represent worthwhile expansions to the German health
care system for patients with depression. The latter aspect
addresses the question of generalizability and transferabil-
ity of findings to routine care.
Implementing the complex intervention of SCM into
everyday clinical practice (with all its restrictions concerning
time, resources, motivation etc.) cannot be carried out in as
standardized a manner as it would be in settings more
prone to research. However, process variables are assessed
in order to ensure treatment adherence to SCM within
our study. A further limitation is that we will not be able
to make inferences about the effectiveness of specific
elements of stepped care, as our design refers to the effect-
iveness of stepped care as a complex intervention.
In contrast to other studies, the SCM examined here
follows a stratified stepped-care approach taking into
account patients’ needs and preferences which may be
clinically more adequate than the more stringent model
of stepped care which begins with the least intensive treat-
ment for each patient regardless of symptom severity. To-
gether with the systematic monitoring aimed at ensuring
an adequate treatment modality and dose, these innova-
tive aspects can provide important findings about how
stepped care should be designed to gain sizeable effects.
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